Scintigraphy 2.0: Faster, smarter prostate cancer monitoring
A new fast CZT SPECT imaging approach allows efficient monitoring of prostate cancer during 177Lu-PSMA therapy. By measuring new bone lesions and total lesion activity, physicians can better predict survival and personalise treatment. The total-body scan takes under 20 minutes, requires no extra tracer, and helps adjust therapy early for improved outcomes.